tiprankstipranks
Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
US Market
JANX
Janux Therapeutics Inc
RESEARCH TOOLSreports
Want to see JANX full AI Analyst Report?

Janux Therapeutics Inc (JANX) Stock Forecast & Price Target

717 Followers
See the Price Targets and Ratings of:

JANX Analyst Ratings

Strong Buy
15Ratings
Strong Buy
13 Buy
1 Hold
1 Sell
Based on 15 analysts giving stock ratings to
Janux
Therapeutics Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

JANX Stock 12 Month Forecast

Average Price Target

$39.79
▲(151.49% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Janux Therapeutics Inc in the last 3 months. The average price target is $39.79 with a high forecast of $100.00 and a low forecast of $14.00. The average price target represents a 151.49% change from the last price of $15.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","101":"$101","34.25":"$34.3","56.5":"$56.5","78.75":"$78.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.78571428571429,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,34.25,56.5,78.75,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.34,20.92923076923077,27.518461538461537,34.107692307692304,40.69692307692307,47.28615384615384,53.87538461538462,60.464615384615385,67.05384615384615,73.64307692307692,80.23230769230769,86.82153846153845,93.41076923076923,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.34,16.29736263736264,18.254725274725274,20.212087912087913,22.169450549450552,24.126813186813187,26.084175824175826,28.041538461538465,29.9989010989011,31.95626373626374,33.91362637362638,35.87098901098902,37.828351648351656,{"y":39.78571428571429,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.34,14.313846153846153,14.287692307692307,14.26153846153846,14.235384615384616,14.20923076923077,14.183076923076923,14.156923076923077,14.13076923076923,14.104615384615384,14.07846153846154,14.052307692307693,14.026153846153846,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.42,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.51,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.34,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$100.00Average Price Target$39.79Lowest Price Target$14.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on JANX
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$45
Buy
184.45%
Upside
Reiterated
05/11/26
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
Evercore ISI Analyst forecast on JANX
Jonathan Miller
Evercore ISI
Evercore ISI
$23→$22
Buy
39.06%
Upside
Reiterated
05/11/26
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISIJanux Therapeutics price target lowered to $22 from $23 at Evercore ISI
LifeSci Capital Analyst forecast on JANX
Oliver McCammon
LifeSci Capital
LifeSci Capital
$60
Buy
279.27%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Rocket Pharmaceuticals (NASDAQ: RCKT) and Evolent Health (NYSE: EVH)
Barclays Analyst forecast on JANX
Etzer Darout
Barclays
Barclays
$14
Sell
-11.50%
Downside
Assigned
05/08/26
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Janux Therapeutics Inc (NASDAQ: JANX) and Progyny (NASDAQ: PGNY)
Piper Sandler Analyst forecast on JANX
Kelsey Goodwin
Piper Sandler
Piper Sandler
$30→$26
Buy
64.35%
Upside
Reiterated
05/08/26
Janux Therapeutics price target lowered to $26 from $30 at Piper SandlerJanux Therapeutics price target lowered to $26 from $30 at Piper Sandler
TD Cowen Analyst forecast on JANX
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
JonesTrading Analyst forecast on JANX
Boris Peaker
JonesTrading
JonesTrading
$28
Buy
76.99%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
Bank of America Securities Analyst forecast on JANX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$24→$21
Buy
32.74%
Upside
Reiterated
05/08/26
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
Wedbush Analyst forecast on JANX
Robert Driscoll
Wedbush
Wedbush
$45→$36
Buy
127.56%
Upside
Reiterated
05/08/26
Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
William Blair Analyst forecast on JANX
Matt Phipps
William Blair
William Blair
$14
Buy
-11.50%
Downside
Reiterated
05/08/26
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
Guggenheim Analyst forecast on JANX
Bradley Canino
Guggenheim
Guggenheim
$68→$58
Buy
266.62%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Stifel Nicolaus Analyst forecast on JANX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$38
Buy
140.20%
Upside
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), Eli Lilly & Co (NYSE: LLY) and Janux Therapeutics Inc (NASDAQ: JANX)
UBS Analyst forecast on JANX
David Dai
UBS
UBS
$57→$15
Hold
-5.18%
Downside
Downgraded
04/15/26
Janux Therapeutics downgraded to Neutral from Buy at UBSJanux Therapeutics downgraded to Neutral from Buy at UBS
Truist Financial Analyst forecast on JANX
Karina Rabayeva
Truist Financial
Truist Financial
$100→$80
Buy
405.69%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Veeva Systems (NYSE: VEEV) and Janux Therapeutics Inc (NASDAQ: JANX)
Cantor Fitzgerald Analyst forecast on JANX
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$150→$100
Buy
532.11%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Progyny (NASDAQ: PGNY) and Concentra Group Holdings Parent, Inc. (NYSE: CON)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on JANX
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$45
Buy
184.45%
Upside
Reiterated
05/11/26
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
Evercore ISI Analyst forecast on JANX
Jonathan Miller
Evercore ISI
Evercore ISI
$23→$22
Buy
39.06%
Upside
Reiterated
05/11/26
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISIJanux Therapeutics price target lowered to $22 from $23 at Evercore ISI
LifeSci Capital Analyst forecast on JANX
Oliver McCammon
LifeSci Capital
LifeSci Capital
$60
Buy
279.27%
Upside
Assigned
05/09/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Rocket Pharmaceuticals (NASDAQ: RCKT) and Evolent Health (NYSE: EVH)
Barclays Analyst forecast on JANX
Etzer Darout
Barclays
Barclays
$14
Sell
-11.50%
Downside
Assigned
05/08/26
Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (NASDAQ: OMDA), Janux Therapeutics Inc (NASDAQ: JANX) and Progyny (NASDAQ: PGNY)
Piper Sandler Analyst forecast on JANX
Kelsey Goodwin
Piper Sandler
Piper Sandler
$30→$26
Buy
64.35%
Upside
Reiterated
05/08/26
Janux Therapeutics price target lowered to $26 from $30 at Piper SandlerJanux Therapeutics price target lowered to $26 from $30 at Piper Sandler
TD Cowen Analyst forecast on JANX
Marc Frahm
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/08/26
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
JonesTrading Analyst forecast on JANX
Boris Peaker
JonesTrading
JonesTrading
$28
Buy
76.99%
Upside
Reiterated
05/08/26
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
Bank of America Securities Analyst forecast on JANX
Alec Stranahan
Bank of America Securities
Bank of America Securities
$24→$21
Buy
32.74%
Upside
Reiterated
05/08/26
Bank of America Securities Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
Wedbush Analyst forecast on JANX
Robert Driscoll
Wedbush
Wedbush
$45→$36
Buy
127.56%
Upside
Reiterated
05/08/26
Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
William Blair Analyst forecast on JANX
Matt Phipps
William Blair
William Blair
$14
Buy
-11.50%
Downside
Reiterated
05/08/26
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
Guggenheim Analyst forecast on JANX
Bradley Canino
Guggenheim
Guggenheim
$68→$58
Buy
266.62%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
Stifel Nicolaus Analyst forecast on JANX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$38
Buy
140.20%
Upside
Reiterated
04/28/26
Analysts Offer Insights on Healthcare Companies: Qiagen (NYSE: QGEN), Eli Lilly & Co (NYSE: LLY) and Janux Therapeutics Inc (NASDAQ: JANX)
UBS Analyst forecast on JANX
David Dai
UBS
UBS
$57→$15
Hold
-5.18%
Downside
Downgraded
04/15/26
Janux Therapeutics downgraded to Neutral from Buy at UBSJanux Therapeutics downgraded to Neutral from Buy at UBS
Truist Financial Analyst forecast on JANX
Karina Rabayeva
Truist Financial
Truist Financial
$100→$80
Buy
405.69%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Veeva Systems (NYSE: VEEV) and Janux Therapeutics Inc (NASDAQ: JANX)
Cantor Fitzgerald Analyst forecast on JANX
Joshua Schimmer
Cantor Fitzgerald
Cantor Fitzgerald
$150→$100
Buy
532.11%
Upside
Reiterated
02/26/26
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (NASDAQ: JANX), Progyny (NASDAQ: PGNY) and Concentra Group Holdings Parent, Inc. (NYSE: CON)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Janux Therapeutics Inc

3 Months
Matt PhippsWilliam Blair
Success Rate
6/13 ratings generated profit
46%
Average Return
+6.32%
Copying Matt Phipps's trades and holding each position for 3 Months would result in 46.15% of your transactions generating a profit, with an average return of +6.32% per trade.
1 Year
Robert DriscollWedbush
Success Rate
2/10 ratings generated profit
20%
Average Return
+6.63%
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of +6.63% per trade.
2 Years
Robert DriscollWedbush
Success Rate
2/10 ratings generated profit
20%
Average Return
-26.78%
Copying Robert Driscoll's trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -26.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

JANX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
27
24
14
19
18
Buy
10
12
5
6
5
Hold
2
1
1
1
1
Sell
0
0
0
1
2
Strong Sell
0
0
0
0
0
total
39
37
20
27
26
In the current month, JANX has received 23 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. JANX average Analyst price target in the past 3 months is 39.79.
Each month's total comprises the sum of three months' worth of ratings.

JANX Financial Forecast

JANX Earnings Forecast

Next quarter’s earnings estimate for JANX is -$0.31 with a range of -$0.92 to $0.16. The previous quarter’s EPS was -$0.39. JANX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.
Next quarter’s earnings estimate for JANX is -$0.31 with a range of -$0.92 to $0.16. The previous quarter’s EPS was -$0.39. JANX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.

JANX Sales Forecast

Next quarter’s sales forecast for JANX is $17.94M with a range of $0.00 to $38.73M. The previous quarter’s sales results were $3.73M. JANX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.
Next quarter’s sales forecast for JANX is $17.94M with a range of $0.00 to $38.73M. The previous quarter’s sales results were $3.73M. JANX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year JANX has Performed in-line its overall industry.

JANX Stock Forecast FAQ

What is JANX’s average 12-month price target, according to analysts?
Based on analyst ratings, Janux Therapeutics, Inc.’s 12-month average price target is 39.79.
    What is JANX’s upside potential, based on the analysts’ average price target?
    Janux Therapeutics, Inc. has 151.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is JANX a Buy, Sell or Hold?
          Janux Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Janux Therapeutics, Inc.’s price target?
            The average price target for Janux Therapeutics, Inc. is 39.79. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $100.00 ,the lowest forecast is $14.00. The average price target represents 151.49% Increase from the current price of $15.82.
              What do analysts say about Janux Therapeutics, Inc.?
              Janux Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of JANX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.